Research Summary

Thomas Hope, MD, is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology. He also serves as the Director of Molecular Therapy. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center and as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. From 2008-2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013.

Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.

An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He current serves as principal investigator on grants from the NIH, the Prostate Cancer Foundation. He is the recipient of numerous accolades in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.

Expertise:
Abdominal Imaging and Nuclear Medicine, and Molecular Imaging and Therapeutics

Professional Interests:
Novel imaging agents, PET/MR, prostate cancer, neuroendocrine tumor, radioligand therapy

Education and Training:
• Medical School: Stanford University School of Medicine, California
• Internship: Kaiser Permanente, San Francisco, California
• Residency: University of California, San Francisco - Diagnostic Radiology
• Fellowship: Stanford Medical Center, California - Body MRI and Nuclear Medicine
• California Medical License
• American Board of Radiology, Certificate in Diagnostic Radiology
• American Board of Nuclear Medicine, Certificate in Nuclear Medicine

Research Funding

  • July 1, 2019 - June 30, 2025 - MELT: Modulation of PSMA Expression for Lutetium Therapy , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2023 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA229354

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • Wahl Mid-Career Leadership Award, Education and Research Foundation for Nuclear Medicine and Molecular Imaging, 2024
  • Hal O’Brien Rising Star Award Winner, Society of Nuclear Medicine and Molecular Imaging, 2020
  • Theragnostics Investigator Award, North American Neuroendocrine Tumor Society, 2018
  • Young Investigator Award, Prostate Cancer Foundation, 2017
  • Henkin Fellowship, Society of Nuclear Medicine and Molecular Imaging, 2016
  • Marc Tetalman Award, Society of Nuclear Medicine and Molecular Imaging, 2016
  • Wylie J. Dodds Research Award, Society of Abdominal Radiology, 2014
  • Roentgen Resident/Fellow Research Award, Radiological Society of North America, 2012
  • Alexander Margulis Society Outstanding Research Award, University of California, San Francisco, 2012
  • Presidents Circle Research Resident Grant, Radiological Society of North America, 2010
  • W.S. Moore Award Nominee, ISMRM, 2007
  • Trainee Research Prize, Radiological Society of North America, 2006

Selected Publications

  1. Herrmann K, Walz J, MacLennan S, Briganti A, Cornford P, Czernin J, Eiber M, Fanti S, Fendler WP, Fizazi K, Gafita A, Gillessen S, Goffin K, Hadaschik B, Hofman MS, Hope TA, Maurer T, Morgans AK, Morris MJ, Murphy DG, Oprea-Lager DE, Ost P, ÓSullivan JM, Rouvière O, Sandhu S, Sartor O, Sathekge MM, Tempany C, Witjes W, Emmett L, Bjartell AS SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.  View on PubMed
  2. Uribe C, Iravani A, Savir-Baruch B, Jacene H, Graves SA, Dewaraja YK, Heath CL, Hope TA Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals.  View on PubMed
  3. Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning.  View on PubMed
  4. Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel FM, Beyer T, Buvat I, Calais J, Dorbala S, Drzezga AE, Herrmann K, Hope TA, Jadvar H, Mankoff DA, Schelbert HR, Weber WA Funding Reductions Threaten the Future of Medical Innovation.  View on PubMed
  5. Akhavanallaf A, Lu Z, Peterson AB, Blakkisrud J, Kurkowska S, Yadav S, Wang C, Uribe C, Stokke C, Rahmim A, Wong KK, Beauregard JM, Hope TA, Sjögreen Gleisner K, Dewaraja YK Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.  View on PubMed
  6. Casey M, Tozzi F, Wang J, Park KM, Bergsland E, Hope T, Kennecke HF, Rose JB, Babicky M, Irani SS, El-Hayek KM, Hilal MA, Asbun HJ, Cleary S, Smeets P, Berrevoet F, Adam M, Rashidian N, Alseidi A, PNET Diagnosis Research Group. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus. Surg Endosc. 2025 May 02.  View on PubMed
  7. Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE, Parikh RA Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.  View on PubMed
  8. Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.  View on PubMed
  9. Matsulevits A, Alves P, Atzori M, Beyh A, Corbetta M, Pup FD, Dulyan L, Foulon C, Hope T, Ioannucci S, Jobard G, Lemaître H, Neville D, Nozais V, Rorden C, Saprikis OV, Sibon I, Sperber C, Teghipco A, Thirion B, Tshimanga LF, Umarova R, Vaidelyte EB, van den Hoven E, Rodriguez EV, Zanola A, Tourdias T, de Schotten MT A global effort to benchmark predictive models and reveal mechanistic diversity in long-term stroke outcomes.  View on PubMed
  10. Hong CW, Yang Y, Remick I, Su P, Itriago-Leon P, Nickel MD, Fautz HP, Majeed W, Bergsland E, Hope TA, Ohliger MA. Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study. AJR Am J Roentgenol. 2025 Apr 16.  View on PubMed
  11. Yadav S, Tuchayi AM, Moradpour M, Jiang F, Juarez R, de Kouchkovsky I, Flavell RR, Aggarwal RR, Hope TA. Pre- or post-chemotherapy: effect on PSMA uptake. EJNMMI Res. 2025 Apr 07; 15(1):36.  View on PubMed
  12. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025 Mar 26.  View on PubMed
  13. Hong CW, Behr SC, Jiang F, Wang Y, Houshmand S, Hope TA Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography.  View on PubMed
  14. Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025 Feb 27.  View on PubMed
  15. Lindenberg L, Hope TA, Lin FI, Rowe SP, Pucar D, Gilbert N, Chicco D, He B, Feuerecker B, Castaldi E, Solnes LB. Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer. J Nucl Med. 2025 Feb 20.  View on PubMed
  16. Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT. Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. Eur Urol Oncol. 2025 Feb 06.  View on PubMed
  17. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 03; 66(1):54-60.  View on PubMed
  18. Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, McConathy J, Oprea-Lager DE, Trimnal L, Zan E, Herrmann K, Deroose CM. SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2025 Jan 03; 66(1):26-33.  View on PubMed
  19. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 01; 131(1):e35612.  View on PubMed
  20. Kong G, Noe G, Chiang C, Herrmann K, Hope TA, Michael M. Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers. J Neuroendocrinol. 2024 Nov 09; e13461.  View on PubMed

Go to UCSF Profiles, powered by CTSI